News

Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate

Nabriva Announces Changes to its Board of Directors

Medizintechnik aus Wiener Neustadt international erfolgreich

Core Facility Tulln leistet wichtige Beiträge zu gesellschaftlichen Herausforderungen

Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital

So klein und schon so böse: Eingefärbte Tumore verraten frühzeitig ihren schlechten Einfluss

contextflow announces mid-seven figures Series A Investment

B&C investiert in österreichisches Tech-Unternehmen contextflow

APEIRON Biologics Announces Changes to Management and Supervisory Boards

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHARMIG mit neuem Legal Counsel

One machine as a one-stop source for respiration valves and sample racks

Scientists develop “scifi-RNA-seq” method for ultra-high-throughput RNA sequencing in single cells

AUSTROMED: Labordiagnostik muss nachhaltig im Gesundheitssystem verankert werden

DNA-based material with tunable properties

Ribbon Biolabs successfully synthesises a 10 kbp DNA molecule using their FullGenes platform

Blood test detects childhood tumors based on their epigenetic profiles

Forschungs-Update zum Welt-Multiple-Sklerose-Tag Forscher*innen widmen sich „verborgenen“ Symptomen der MS

Lexogen gains ISO 9001:2015 quality management certification

27 MAY 2021 POSITIVE PHASE 1 RESULTS WITH IMMUNOTHERAPIES TARGETING PCSK9 TO TREAT HYPERCHOLESTEROLEMIA PUBLISHED BY THE EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY